Business news from Ukraine

“Novo Nordisk” has provided Ukraine with more than 900 mln hryvnias worth of humanitarian aid

25 July , 2023  

Since the beginning of the full-scale invasion, pharma company Novo Nordisk has provided Ukraine with humanitarian and charitable assistance in various ways for more than 900 million UAH.

According to its press release, in addition, throughout 2019-2023, more than 100 Ukrainian hospitals have received equipment for continuous blood glucose measurement totaling UAH 8 million from the company.

“In the first months of the war, to avoid shortages of insulin and other vital drugs, we transferred to the Ministry of Health of Ukraine a six-month supply of insulins of different types and more than a third of the annual need for blood clotting factors. Together we were able to provide insulins to more than 50 thousand patients in different parts of Ukraine”, – the press release quotes the words of the General Director of “Novo Nordisk Ukraine” Vladislav Moroz.

It is specified that since the beginning of the full-scale war humanitarian aid from Novo Nordisk with insulins and other medicines has been delivered to hot spots in the temporarily occupied territories in cooperation with volunteers and charitable organizations, in particular, BF Zhiznelyub, BF Patients of Ukraine, BF Save Mariupol.

In addition, Novo Nordisk joined an international initiative to rebuild Mykolayiv and Mykolayiv region affected by the war.

“Novo Nordisk has allocated $5 million, which will be used to restore critical infrastructure in Nikolaev, in particular water and power plants, and humanitarian aid to the residents of the city and region. A separate budget is provided for the restoration of medical infrastructure and additional supplies of medical equipment needed by hospitals in Mykolaiv and the region,” Moroz said.

Novo Nordisk is a leading global medical company founded in 1923 and headquartered in Denmark. The company specializes in overcoming diabetes and other serious chronic diseases such as obesity, rare blood clotting and endocrine disorders. The company employs about 55,000 people in 80 countries and sells its products in about 170 countries.

,